🇺🇸 FDA
Patent

US 7700274

Compositions and methods in cancer associated with altered expression of KCNJ9

granted A61KA61K2039/53A61K38/00

Quick answer

US patent 7700274 (Compositions and methods in cancer associated with altered expression of KCNJ9) held by Sagres Discovery, Inc. expires Mon Apr 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Sagres Discovery, Inc.
Grant date
Tue Apr 20 2010 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Apr 15 2030 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
5
CPC classes
A61K, A61K2039/53, A61K38/00, A61P, A61P35/00